Semax

WHAT IT IS

Semax is a heptapeptide built from the 4-10 fragment of ACTH, a hormone normally involved in the stress response, with a short additional sequence added to extend how long it remains active in the body.

It does not carry the hormonal effects on the adrenal glands that full ACTH has. Researchers were interested in whether this fragment retained effects on brain signaling separate from that hormonal activity.

It was developed decades ago in Russia and is registered there as a prescription nasal drop for indications including recovery after ischemic stroke and certain attention-related conditions in children. That registration reflects a different regulatory system than the FDA, and it does not carry over to the United States.

FDA status: Not currently FDA-approved for any use in the United States.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published research, spanning small Russian clinical studies and a larger body of animal work, has looked at:

• Recovery of neurological function after ischemic stroke
• Brain-derived neurotrophic factor, BDNF, expression and related neurotrophic signaling
• Attention, learning and memory tasks in rodent models
• Markers of oxidative stress and neuroinflammation in animal brain tissue
• Cognitive performance measures in small human studies conducted in Russia
• Potential neuroprotective effects during periods of reduced blood flow to the brain

PROPOSED BIOLOGICAL MECHANISMS

The leading hypothesis is that Semax increases expression of BDNF and related neurotrophic factors, which are proteins that support the survival and adaptability of neurons.

Animal studies also describe effects on neurotransmitter systems and antioxidant activity in brain tissue, which researchers propose could contribute to neuroprotection during ischemic stress.

Most of this mechanistic detail comes from rodent brain tissue and cell culture, not from imaging or biomarker studies confirming the same activity in living human brains.

These are proposed pathways under active study, not confirmed mechanisms of action established in people.

AREAS OF RESEARCH INTEREST

• Whether neurotrophic signaling changes seen in animals occur in humans and at what exposure
• Whether small Russian clinical studies would replicate under independent, internationally reviewed trial designs
• How Semax compares with existing FDA-approved stroke interventions in terms of tested efficacy
• Whether cognitive effects reported in limited studies hold up in larger, blinded, placebo-controlled human trials

WHAT THE EVIDENCE CURRENTLY SUGGESTS

Animal research on Semax is fairly extensive and reports consistent effects on neurotrophic markers and behavioral measures of learning and memory in rodents.

Human evidence is much more limited and comes largely from studies conducted in Russia, some of which are small, use varied designs and have not been replicated through the kind of large, independent, peer-reviewed randomized trials that regulatory agencies like the FDA typically require.

Semax is registered as a medical product in Russia for specific indications, which is a distinct regulatory pathway with its own evidentiary standard and independent international review.

A NOTE ON "N-ACETYL" VERSIONS

Products marketed as "N-Acetyl Semax Amidate" are chemically modified analogs of Semax, with an acetyl group added at the N-terminus and an amide group at the C-terminus. These modifications are typically described as making the peptide more stable.

There is little to no published human research specifically on this N-acetylated, amidated form. Findings discussed above relate to Semax itself and should not be assumed to transfer equally to this modified version.

Anyone considering a product labeled this way should recognize it as a distinct chemical entity from the Semax studied in the research cited here.